Bildkälla: Stockfoto

Pila Pharma Q1’22: New project revealed - Redeye

Redeye leaves its comment on Pila Pharma following the announcement of its Q1 report. Highlights include revealing a new pipeline candidate and certification of API. The financials were broadly in line with expectations.

Redeye leaves its comment on Pila Pharma following the announcement of its Q1 report. Highlights include revealing a new pipeline candidate and certification of API. The financials were broadly in line with expectations.
Börsvärldens nyhetsbrev
ANNONSER